Data Sheet (Cat.No.T14918)

TargetMol

CDK9-IN-2

Chemical Properties



CAS No. : 1263369-28-3

Formula: C23H25ClFN5

Molecular Weight: 425.93

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CDK9-IN-2 is a specific CDK9 inhibitor with an IC50 of 5 nM in the A2058 skin cell line (72 hours) and 7 nM in the H929 multiple myeloma cell line (72 hours).
Targets(IC50)	CDK
In vitro	CDK9-IN-2, at a concentration of 200 nM, decreases MEPCE expression, suggesting MEPCE serves as a pharmacodynamic indicator for CDK9 inhibitors. Moreover, MCL1 protein levels are diminished within 2 hours of CDK9-IN-2 treatment, with further reduction observed after 16 hours of exposure to a higher concentration of 500 nM.

Solubility Information

Solubility	DMSO: 150 mg/mL (352.17 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.7 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3478 mL	11.739 mL	23.478 mL
5 mM	0.4696 mL	2.3478 mL	4.6956 mL
10 mM	0.2348 mL	1.1739 mL	2.3478 mL
50 mM	0.047 mL	0.2348 mL	0.4696 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1.